Johnson & Johnson

NYSE:JNJ   3:59:58 PM EDT
170.37
+1.87 (+1.11%)
4:00:03 PM EDT: $170.53 +0.16 (+0.09%)
Mergers / Acquisitions

Janssen Acquires Rights To Novel Gene Therapy, Pioneering Treatment Solutions For Late-Stage Age-Related Macular Degeneration

Published: 12/02/2020 13:25 GMT
Johnson & Johnson (JNJ) - Janssen Acquires Rights to Novel Gene Therapy, Pioneering Treatment Solutions for Late-stage Age-related Macular Degeneration.
Janssen Pharmaceuticals Inc- Financial Terms of Transaction With Hemera Biosciences Are Not Being Disclosed.